Published in Vaccine Weekly, July 26th, 2000
"TRAP, a candidate malaria vaccine antigen, is required for Plasmodium sporozoite gliding motility and cell invasion," explained S. Gantt and colleagues, New York University. "For the first time, the ability of antibodies against TRAP to inhibit sporozoite infectivity in vivo is evaluated in detail."
Gantt et al. published their study in the journal Infection and Immunity ("Antibodies against thrombospondin-related anonymous protein do not inhibit...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.